The FGFR inhibitor UPR1376, a chloroacetamide derivative has demonstrated preclinical anti-tumour activity in FGFR1 amplified lung cancer cell lines with acquired resistance to infigratinib[78]. This evidence concerns the gene FGFR1 and lung carcinoma.